Longitudinal nucleocapsid antibody testing reveals undocumented SARS-CoV-2 infections in patients with lung cancer

Ananda M Rodilla; Rajesh M Valanparambil; Philip C Mack; Chih-Yuan Hsu; Jazz Cagan; Sooyun C Tavolacci; Juan Manuel Carreño; Rachel Brody; Amy Moore; Jennifer C King; Jorge E Gomez; Nicholas Rohs; Christian Rolfo; Paul A Bunn Jr; David E Gerber; John D Minna; Florian Krammer; Suresh S Ramalingam; Adolfo García-Sastre; Yu Shyr; Rafi Ahmed; Fred R Hirsch

doi:10.1016/j.ccell.2023.09.017

Longitudinal nucleocapsid antibody testing reveals undocumented SARS-CoV-2 infections in patients with lung cancer

Cancer Cell. 2023 Nov 13;41(11):1838-1840. doi: 10.1016/j.ccell.2023.09.017. Epub 2023 Oct 19.

Authors

Ananda M Rodilla¹, Rajesh M Valanparambil², Philip C Mack¹, Chih-Yuan Hsu³, Jazz Cagan¹, Sooyun C Tavolacci¹, Juan Manuel Carreño⁴, Rachel Brody⁵, Amy Moore⁶, Jennifer C King⁷, Jorge E Gomez¹, Nicholas Rohs¹, Christian Rolfo¹, Paul A Bunn Jr⁸, David E Gerber⁹, John D Minna⁹, Florian Krammer¹⁰, Suresh S Ramalingam¹¹, Adolfo García-Sastre¹², Yu Shyr³, Rafi Ahmed², Fred R Hirsch¹³

Affiliations

¹ Center for Thoracic Oncology, Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai, New York, NY, USA.
² Emory Vaccine Center, Emory University, Atlanta, GA, USA; Department of Microbiology and Immunology, Emory University, Atlanta, GA, USA.
³ Department of Biostatistics, Vanderbilt University, Nashville, TN, USA.
⁴ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
⁵ Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁶ LUNGevity Foundation, Bethesda, MD, USA.
⁷ GO(2) For Lung Cancer, Washington, DC, USA.
⁸ Division of Medical Oncology, University of Colorado Cancer Center, Aurora, CO, USA.
⁹ Hamon Center for Therapeutic Oncology Research, Departments of Internal Medicine and Pharmacology UT Southwestern Medical Center, Dallas, TX, USA.
¹⁰ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
¹¹ Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
¹² Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
¹³ Center for Thoracic Oncology, Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: fred.hirsch@mssm.edu.

PMID: 37863065
DOI: 10.1016/j.ccell.2023.09.017

Abstract

Patients diagnosed with lung cancer (LC) exhibit increased susceptibility to SARS-CoV-2 infection. Rodilla et al. monitor the levels of plasma anti-nucleocapsid antibodies within a cohort of fully vaccinated LC patients and reveal that the actual infection rate is nearly twice the documented rate, indicating a significant prevalence of unreported cases.

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

COVID-19 Testing
COVID-19*
Humans
Immunologic Tests
Lung Neoplasms*
Nucleocapsid
SARS-CoV-2

Abstract

Publication types

MeSH terms

Grants and funding